Advances in Pharmacoepidemiology and Drug Safety

Burylo A

Publications

• Research Article
  Factors Affecting Long-Term Safety of Trastuzumab in Patients with Early HER2-Positive Breast Cancer
  Author(s): Boekhout AH, Werkhoven ED, Liebergen R, Korse CM, Burylo A, Trip AK, Beijnen JH and Schellens JH Boekhout AH, Werkhoven ED, Liebergen R, Korse CM, Burylo A, Trip AK, Beijnen JH and Schellens JH
  
  Background: Trastuzumab treatment is associated with cardiac dysfunction. We evaluated the incidence of cardiotoxicity during and long-term after trastuzumab treatment in an unselected early breast cancer population. Methods: This study included a retrospective part, the chemotherapy- and trastuzumab treatment period and a prospective part, the period of data collection long-term after trastuzumab treatment. Cardiac evaluation included left ventricular ejection fraction (LVEF) changes and an evaluation of symptomatic cardiotoxicity. Cardiac events were defined as a decrease of 10 percentage points in LVEF compared with baseline and to an absolute LVEF of below 50%. Secondary outcomes included the evaluation of cardiac markers (B-type natriuretic peptide and troponins) and single nucleotide polymorphisms (SNPs) in the HER2 gene .. View More»
  DOI: 10.4172/2167-1052.1000160

  Abstract PDF